Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients

Table 5 Comparison of adverse events between cisplatin combined with IL-2 versus cisplatin alone

Study	Study size (N)		Myelotoxicity				Nausea/vomiting				Chest pain				Fever
	Study size (N)		Group 1		Group 2		Group 1		Group 2		Group 1	Group 2			Group 1		Group 2
	Group 1	Group 2	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Changjie H 2001 [15]	30	30	–	–	–	–	13	43.3	0	0	–	–	–	–	10	33.3	0	0
Xiuzhi Y 2001 [16]	40	20	14	35	11	55	5	12.5	5	25	–	–	–	–	–	–	–	–
Zhuo S 2004 [17]	32	30	3	9.3	3	10	5	15.6	4	13.3	–	–	–	–	–	–	–	–
Junyan W 2005 [18]	48	34	–	–	–	–	12	25	8	23.5	–	–	–	–	18	37.5	11	32.4
Haiying X 2009 [19]	35	28	3	9	8	28.6	8	22.9	9	32.1	–	–	–	–	12	36.4	1	4
Xiaoxia H 2009 [20]	37	35	13	35.1	10	25	11	29.7	11	31.4	–	–	–	–	4	10.8	3	8.6
Lizheng C 2009 [21]	46	40	–	–	–	–	–	–	–	–	12	26.1	4	10	–	–	–	–
Jinguang C 2009 [22]	31	31	–	–	–	–	6	20	8	26	5	16	3	10	6	19	2	6
Junfeng W 2010 [23]	41	41	–	–	–	–	19	46.4	21	51.2	6	14.6	8	19.5	21	51.2	15	36.3
Jingping Z 2010 [24]	63	61	4	6.3	3	4.9	7	11.1	2	3.3	12	19.5	9	14.8	13	20.6	4	6.6
Cheng X 2010 [25]	41	41	6	19.4	8	25.8	11	35.5	7	26.6	7	22.6	4	12.9	9	29	7	26.6
Fang S 2011 [26]	30	30	2	6.6	3	10	4	13.3	6	20	7	23.3	5	16.6	12	40	9	30
Yan Q 2011 [28]	34	34	2	4.8	2	5.7	2	4.8	3	8.6	5	12.2	6	17.1	3	7.3	4	11.4
Li J 2013 [29]	41	35	16	42.1	13	37.1	9	23.7	8	22.8	6	15.8	4	11.4	2	7.1	3	8.5
Lijie H 2014 [30]	38	35	3	10	3	10	3	10	3	10	4	13.3	3	10	6	20	3	10
Miao H 2016 [31]	30	30	4	12.9	5	16.6	11	35.5	10	33.3	24	77.4	20	66.6	–	–	–	–
	P > 0.05						P > 0.05			P > 0.05				P < 0.05

IL-2 interleukin-2, N, cases; Values are given as number of patients (%). Group 1 = cisplatin+IL-2; Group 2 = cisplatin alone

ISSN: 1471-2407